Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (11920)

2/11/2019 9:46:35 PM

From: Colavita365

Read Replies (1) | Respond to of 12873

Dr. Vivian Boniuk used to have a Biography on the Nanoviricides' website as their Chief Medical Officer on the Executive Officers page. It was purged from the website a month or two after her brother Milton Boniuk resigned from the Board, citing in his resignation letter that the company was not following up and carrying through with the forensic audit the Audit Committee had initiated .of Theracour and Diwan relating to matters of conflicts of interest un the Theracour-NNVC agreements and in-licensing.
So all may not be well between Dr. Ms. B and Diwan as you seem to think.

Here is the text of Dr. Boniuk's letter:

By E-mail

Anil R. Diwan, President and Chairman
Mukund S. Kulkarni, Director
Stanley Glick, Director
NanoViricides, Inc.
1 Controls Drive,
Shelton, CT 06484

Dear Dr. Diwan and Members of the Board:

After careful reflection, and based upon what appear to be irreconcilable disagreements between me, on the one hand, and the Chief Executive Officer, other members of management, and the Board, on the other, I have decided to submit this letter as my resignation from the Board of NanoViricides, Inc., and from all Committees of the Company.

I have reluctantly reached this conclusion on the basis of, among other things, management’s repeated refusal to provide the audit committee (on which I have served) with information regarding related party transactions, including the propriety of charges by TheraCour Pharma, Inc. to NanoViricides. As you know, the request for that information was made pursuant to a unanimous resolution of the audit committee. I also object to the fact that management has consistently refused to allow a proper forensic audit of the books and records of NanoViricides so that the audit committee can discharge its fiduciary duties. In addition, among other reasons for my resignation, I object to the proposal that the Chief Executive Officer’s employment agreement be extended for three years when the audit committee has not received the information needed for its investigation and no analysis has been done of the impact of that extension on the Company. That proposal has been made notwithstanding the audit committee’s unanimous recommendation on July 3rd that the employment agreement be extended for only 30 days.

	Sincerely,

	Milton Boniuk, M.D.